MCID: END041
MIFTS: 60

Endometrial Adenocarcinoma

Categories: Cancer diseases, Reproductive diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Endometrial Adenocarcinoma

MalaCards integrated aliases for Endometrial Adenocarcinoma:

Name: Endometrial Adenocarcinoma 11 14 71
Endometrial Endometrioid Adenocarcinoma 11 16 71 33
Endometrial Endometrioid Adenocarcinoma, Variant with Squamous Differentiation 5 16
Endometrial Adenoacanthoma 11 71
Endometrial Endometrioid Adenocarcinoma with Squamous Differentiation 11
Endometrioid Carcinoma of Endometrium 11
Endometrioid Adenomas and Carcinomas 11
Adenocarcinoma of the Endometrium 11
Endometrioid Adenoma or Carcinoma 11
Adenocarcinoma of Endometrium 11
Endometrium Adenocarcinoma 16
Adenocarcinoma of Uterus 11

Classifications:



External Ids:

Disease Ontology 11 DOID:2870
SNOMED-CT 68 123845008 762458004
ICD11 33 671511103
UMLS 71 C0279763 C1153706 C1336905

Summaries for Endometrial Adenocarcinoma

Disease Ontology: 11 An endometrial carcinoma that derives from epithelial cells of glandular origin.

MalaCards based summary: Endometrial Adenocarcinoma, also known as endometrial endometrioid adenocarcinoma, is related to adenocarcinoma and endometrial hyperplasia. An important gene associated with Endometrial Adenocarcinoma is MALAT1 (Metastasis Associated Lung Adenocarcinoma Transcript 1), and among its related pathways/superpathways are Signal Transduction and Phospholipase-C Pathway. The drugs Bupivacaine and Dexmedetomidine have been mentioned in the context of this disorder. Affiliated tissues include uterus, lymph node and ovary, and related phenotypes are neoplasm and muscle

Related Diseases for Endometrial Adenocarcinoma

Diseases related to Endometrial Adenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 545)
# Related Disease Score Top Affiliating Genes
1 adenocarcinoma 32.0 TP53 PTEN MALAT1 FGFR2 EGFR AKT1
2 endometrial hyperplasia 31.3 TP53 PTEN PGR ESR1
3 endometrial cancer 31.2 TP53 PTEN PIK3R2 PGR MIR200B MIR200A
4 adenomyosis 31.1 TP53 PTEN ESR1
5 cervical adenocarcinoma 30.9 TP53 PGR ESR1
6 carcinosarcoma 30.8 TP53 PTEN PGR EGFR
7 estrogen excess 30.7 PTEN PGR ESR1
8 large cell neuroendocrine carcinoma 30.7 TP53 MIR200B EGFR
9 endocervical adenocarcinoma 30.7 TP53 PTEN PGR ESR1
10 neuroendocrine carcinoma 30.7 PTEN PGR ESR1
11 papillary serous adenocarcinoma 30.6 TP53 PGR ESR1
12 squamous cell carcinoma 30.6 TP53 PTEN MALAT1 FGFR2 EGFR AKT1
13 serous cystadenocarcinoma 30.6 TP53 PTEN PGR MIR152 ESR1 AKT1
14 lynch syndrome 30.5 TP53 PTEN PGR ESR1 EGFR AKT1
15 teratoma 30.5 TP53 PTEN ESR1 AKT1
16 leiomyosarcoma 30.5 TP53 PGR ESR1
17 endometriosis 30.5 TP53 PTEN PGR MIR200B MIR200A ESR1
18 endometrial stromal sarcoma 30.5 TP53 PGR MALAT1 ESR1
19 bizarre leiomyoma 30.5 TP53 PGR ESR1
20 papilloma 30.4 TP53 PTEN EGFR AKT1
21 myoma 30.3 TP53 PGR ESR1 EGFR
22 renal cell carcinoma, papillary, 1 30.3 TP53 PTEN EGFR AKT1
23 lymphatic system disease 30.3 TP53 MIR204 MIR200B MIR193A
24 uterine corpus endometrial carcinoma 30.3 TP53 PTEN PGR FGFR2
25 bilateral breast cancer 30.3 TP53 PTEN PGR ESR1
26 diffuse peritoneal leiomyomatosis 30.3 PGR ESR1
27 colorectal adenocarcinoma 30.3 TP53 PTEN MIR193A EGFR AKT1
28 fibroma 30.3 PGR MALAT1 ESR1
29 uterine corpus cancer 30.2 TP53 PTEN PGR ESR1 EGFR AKT1
30 adenosarcoma 30.2 TP53 PGR ESR1
31 endometrial disease 30.2 PGR MIR200A ESR1
32 ovary adenocarcinoma 30.2 TP53 PTEN PGR MIR152 ESR1 EGFR
33 ovarian clear cell carcinoma 30.2 TP53 PTEN AKT1
34 endometriosis of ovary 30.2 PTEN PGR ESR1
35 uterine anomalies 30.1 MIR204 MIR200B MIR200A MIR193A MIR152 ESR1
36 cervix carcinoma 30.1 TP53 PTEN PGR MIR200A MIR193A ESR1
37 rectum cancer 30.1 TP53 MIR200A MIR193A EGFR
38 endosalpingiosis 30.1 TP53 ESR1
39 basal cell nevus syndrome 30.1 TP53 PTEN AKT1
40 transitional cell carcinoma 30.1 TP53 PTEN FGFR2 EGFR
41 gastric adenocarcinoma 30.1 TP53 PTEN FGFR2 AKT1
42 ovarian disease 30.0 TP53 PTEN PGR MIR204 MIR202 MIR200B
43 rhabdomyosarcoma 30.0 TP53 PTEN ESR1 EGFR AKT1
44 kidney cancer 30.0 TP53 MIR204 MIR200B MIR193A MALAT1 EGFR
45 basal cell carcinoma 29.9 TP53 PTEN MIR200B EGFR AKT1
46 intestinal benign neoplasm 29.9 TP53 PTEN MIR200A MIR193A EGFR AKT1
47 colonic benign neoplasm 29.9 TP53 PTEN MIR200A ESR1 EGFR AKT1
48 hemangioma 29.9 TP53 PTEN PGR ESR1 EGFR AKT1
49 head and neck cancer 29.8 TP53 PTEN MIR204 MIR200B MIR200A MIR193A
50 gastrointestinal stromal tumor 29.8 TP53 PTEN MIR204 FGFR2 ESR1 EGFR

Graphical network of the top 20 diseases related to Endometrial Adenocarcinoma:



Diseases related to Endometrial Adenocarcinoma

Symptoms & Phenotypes for Endometrial Adenocarcinoma

MGI Mouse Phenotypes related to Endometrial Adenocarcinoma:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 neoplasm MP:0002006 9.86 AKT1 EGFR ESR1 FGFR2 PGR PIK3R2
2 muscle MP:0005369 9.76 AKT1 EGFR ESR1 FGFR2 PGR PIK3R2
3 adipose tissue MP:0005375 9.5 AKT1 EGFR ESR1 FGFR2 PTEN RHOXF1
4 reproductive system MP:0005389 9.32 AKT1 EGFR ESR1 FGFR2 MIR200B NDC80

Drugs & Therapeutics for Endometrial Adenocarcinoma

Drugs for Endometrial Adenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 125)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Bupivacaine Approved, Investigational Phase 4 2180-92-9, 38396-39-3 2474
2
Dexmedetomidine Approved, Experimental, Vet_approved Phase 4 86347-14-0, 113775-47-6 68602 5311068
3
Ketamine Approved, Vet_approved Phase 4 6740-88-1, 1867-66-9 3821
4 Anesthetics Phase 4
5 Neurotransmitter Agents Phase 4
6 Adrenergic alpha-Agonists Phase 4
7 Adrenergic Agonists Phase 4
8 Adrenergic Agents Phase 4
9 Excitatory Amino Acid Antagonists Phase 4
10 Anesthetics, Local Phase 4
11 Anesthetics, Intravenous Phase 4
12 Anesthetics, General Phase 4
13 Anesthetics, Dissociative Phase 4
14 Hypnotics and Sedatives Phase 4
15 Analgesics, Non-Narcotic Phase 4
16 Analgesics Phase 4
17
Doxorubicin Approved, Investigational Phase 3 23214-92-8 31703
18
Cisplatin Approved Phase 3 15663-27-1 2767 5702198 441203
19
Lenograstim Approved, Investigational Phase 3 135968-09-1
20
Pembrolizumab Approved Phase 3 1374853-91-4 254741536
21
Metformin Approved Phase 2, Phase 3 1115-70-4, 657-24-9 4091
22 Liposomal doxorubicin Phase 3
23 Adjuvants, Immunologic Phase 3
24 Hypoglycemic Agents Phase 2, Phase 3
25 Estrogens Phase 3
26 Hormones Phase 3
27 Hormone Antagonists Phase 3
28 Estrogens, Conjugated (USP) Phase 3
29
Medroxyprogesterone acetate Approved, Investigational Phase 2 520-85-4, 71-58-9 6279 10631
30
Sunitinib Approved, Investigational Phase 2 557795-19-4 5329102
31
Amifostine Approved, Investigational Phase 2 20537-88-6 2141
32
Trastuzumab Approved, Investigational Phase 2 180288-69-1
33
Thalidomide Approved, Investigational, Withdrawn Phase 2 50-35-1 5426
34
Nintedanib Approved Phase 2 656247-17-5 135423438 9809715
35
Everolimus Approved Phase 2 159351-69-6 70789204 6442177
36
Letrozole Approved, Investigational Phase 2 112809-51-5 3902
37
Ipilimumab Approved Phase 2 477202-00-9
38
Levoleucovorin Approved, Experimental, Investigational Phase 1, Phase 2 68538-85-2, 58-05-9, 73951-54-9 149436 6006
39
Gemcitabine Approved Phase 1, Phase 2 95058-81-4, 122111-03-9 60750
40
Niraparib Approved, Investigational Phase 1, Phase 2 1038915-60-4 24958200
41
Irinotecan Approved, Investigational Phase 1, Phase 2 97682-44-5, 100286-90-6 60838
42
Fluorouracil Approved Phase 1, Phase 2 51-21-8 3385
43
Fulvestrant Approved, Investigational Phase 2 129453-61-8 17756771 104741
44
Exemestane Approved, Investigational Phase 2 107868-30-4 60198
45
Sirolimus Approved, Investigational Phase 1, Phase 2 53123-88-9 5284616 6436030
46
Anastrozole Approved, Investigational Phase 1, Phase 2 120511-73-1 2187
47
Nivolumab Approved Phase 2 946414-94-4
48
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
49
Clotrimazole Approved, Vet_approved Phase 2 23593-75-1 2812
50
Olaparib Approved Phase 1, Phase 2 763113-22-0 23725625

Interventional clinical trials:

(show top 50) (show all 77)
# Name Status NCT ID Phase Drugs
1 Effects of Local Wound Infiltration With Ketamine Versus Dexmedetomidine Added to Bupivacaine on Inflammatory Cytokines Response After Total Abdominal Hysterectomy Completed NCT03164590 Phase 4 Ketamine;dexmedetomidine;bupivacaine
2 A Randomized Phase III Study of Tumor Volume Directed Pelvic Plus or Minus Para-Aortic Irradiation Followed by Cisplatin and Doxorubicin or Cisplatin, Doxorubicin and Paclitaxel for Advanced Endometrial Carcinoma Completed NCT00006011 Phase 3 Doxorubicin Hydrochloride;Cisplatin;Paclitaxel
3 A Phase III Randomized Clinical Trial of Laparoscopic Pelvic and Para-Aortic Node Sampling With Vaginal Hysterectomy and BSO Versus Open Laparotomy With Pelvic and Para-Aortic Node Sampling and Abdominal Hysterectomy and BSO in Endometrial Adenocarcinoma and Uterine Sarcoma, Clinical Stage I, IIA, Grade I, II, III Completed NCT00002706 Phase 3
4 A Phase III Randomized, Placebo-Controlled Study of Pembrolizumab (MK-3475, NSC #776864) in Addition to Paclitaxel and Carboplatin for Measurable Stage III or IVA, Stage IVB or Recurrent Endometrial Cancer Active, not recruiting NCT03914612 Phase 3 Carboplatin;Paclitaxel
5 A Phase III Randomized Trial of Radiation +/- Pembrolizumab (MK-3475) for Newly Diagnosed Early Stage High Intermediate Risk Mismatch Repair Deficient (dMMR) Endometrioid Endometrial Cancer Active, not recruiting NCT04214067 Phase 3
6 Short Course Adjuvant Vaginal Cuff Brachytherapy (VCB) in Early Endometrial Cancer Compared to Standard of Care (SAVE) Active, not recruiting NCT03422198 Phase 3
7 A Randomized Phase II/III Study of Paclitaxel/Carboplatin/Metformin (NSC#91485) Versus Paclitaxel/Carboplatin/Placebo as Initial Therapy for Measurable Stage III or IVA, Stage IVB, or Recurrent Endometrial Cancer Active, not recruiting NCT02065687 Phase 2, Phase 3 Carboplatin;Metformin Hydrochloride;Paclitaxel
8 A Randomized Double-Blinded Trial of Estrogen Replacement Therapy Versus Placebo in Women With Stage I or II Endometrial Adenocarcinoma Terminated NCT00002976 Phase 3 conjugated estrogens
9 The Effect of Neoadjuvant Depot Medroxyprogesterone Acetate on Glandular Cellularity in Women With Complex Atypical Hyperplasia or Grade 1-2 Endometrial Adenocarcinoma Awaiting Hysterectomy Unknown status NCT02335203 Phase 2 Depot medroxyprogesterone acetate
10 A Phase II Randomised Clinical Trial of Mirena® ± Metformin ± Weight Loss Intervention in Patients With Early Stage Cancer of the Endometrium Unknown status NCT01686126 Phase 2 Levonorgestrel;Metformin
11 Phase II Study of Fertility-sparing Management Using High-dose Oral Progestin in Young Women With Stage I Endometrial Adenocarcinoma With Grade 2 Differentiation or Superficial Myomectomy Invasion Unknown status NCT03567655 Phase 2 Farlutal tab. 500mg/ Pfizer
12 A Phase 2 Study of Sunitinib Malate in Recurrent or Metastatic Endometrial Carcinoma Completed NCT00478426 Phase 2 Sunitinib Malate
13 A Phase II Evaluation of Copanlisib (BAY 80-6946), a Selective Inhibitor of PI3KCA, in Patients With Persistent or Recurrent Endometrial Carcinoma Harboring PIK3CA Hotspot Mutations Completed NCT02728258 Phase 2 Copanlisib
14 A Phase II Pilot Investigation Of The Relationship Of Short Term Depo-Provera (Medroxyprogesterone Acetate) Exposure To The Morphologic , Biochemical, And Molecular Changes In Primary Endometroid Adenocarcinoma of the Uterine Corpus Completed NCT00064025 Phase 2 Medroxyprogesterone
15 A Phase II Trial of AMG 386, a Selective Angiopoietin 1/2 Neutralizing Peptibody, in Patients With Persistent/Recurrent Carcinoma of the Endometrium Completed NCT01210222 Phase 2
16 Efficacy of the Oncoxin-Viusid® Oral Solution in Reducing the Adverse Reactions of Chemotherapy and Radiotherapy in Patients Diagnosed With Cervical Cancer and Endometrial Adenocarcinoma. Completed NCT03540407 Phase 2
17 Megestrol Acetate Plus Metformin to Megestrol Acetate in Patients With Endometrial Atypical Hyperplasia or Early Stage Endometrial Adenocarcinoma Completed NCT01968317 Phase 2 Megestrol acetate and metformin;Megestrol acetate
18 Phase II Study of Pembrolizumab in Combination With Carboplatin and Paclitaxel for Advanced or Recurrent Endometrial Adenocarcinoma Completed NCT02549209 Phase 2 Pembrolizumab;Paclitaxel;Carboplatin
19 Phase II Trial of Paclitaxel and Carboplatin With Amifostine in Advanced Recurrent or Refractory Endometrial Adenocarcinoma Completed NCT00003127 Phase 2 amifostine trihydrate;carboplatin;paclitaxel
20 A Phase II Evaluation of Gemcitabine (Gemzar®, LY188011) in the Treatment of Recurrent or Persistent Endometrial Carcinoma Completed NCT00820898 Phase 2 Gemcitabine Hydrochloride
21 A Phase II Study of CCI-779 in Patients With Metastatic and/or Locally Advanced Recurrent Endometrial Cancer Completed NCT00072176 Phase 2 temsirolimus
22 A Phase II Study of Postoperative Intensity Modulated Radiation Therapy (IMRT) With Concurrent Cisplatin and Bevacizumab Followed by Carboplatin and Paclitaxel for Patients With Endometrial Cancer Completed NCT01005329 Phase 2 Carboplatin;Cisplatin;Paclitaxel
23 A Phase II Evaluation of Trastuzumab (MoAb HER2) in Patients With Advanced, Recurrent or Persistent Endometrial Carcinoma With or Without Prior Chemotherapy Completed NCT00006089 Phase 2
24 A Phase II Evaluation of Brivanib (BMS582664), an Oral, Multitargeted Growth Factor Tyrosine Kinase Inhibitor in the Treatment of Recurrent or Persistent Endometrial Carcinoma Completed NCT00888173 Phase 2 Brivanib Alaninate
25 A Phase II Evaluation of Thalidomide (NSC #66847, IND 48832) in the Treatment of Recurrent of Persistent Endometrial Carcinoma Completed NCT00025467 Phase 2 thalidomide
26 A Phase II Evaluation of AZD6244 (NSC #748727) in the Treatment of Recurrent or Persistent Endometrial Carcinoma Completed NCT01011933 Phase 2 Selumetinib
27 A Phase II Evaluation of Cediranib (Recentin; AZD2171, IND#72740, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma Completed NCT01132820 Phase 2 Cediranib Maleate
28 A Phase II Evaluation of Ixabepilone (BMS-247550) [NCI-Supplied Agent, NSC #710428]) in the Treatment of Recurrent or Persistent Endometrial Carcinoma Completed NCT00095979 Phase 2 ixabepilone
29 A Phase II Evaluation of Dalantercept, a Novel Soluble Recombinant Activin Receptor-Like Kinase 1 (ALK-1) Inhibitor Receptor-Fusion Protein, in the Treatment of Recurrent or Persistent Endometrial Carcinoma Completed NCT01642082 Phase 2
30 A Phase II Evaluation of BIBF 1120 in the Treatment of Recurrent or Persistent Endometrial Carcinoma Completed NCT01225887 Phase 2 Nintedanib
31 A Phase II, 2-Stage, 2-Arm PIK3CA Mutation Stratified Trial of MK-2206 in Recurrent or Advanced Endometrial Cancer Completed NCT01307631 Phase 2 Akt Inhibitor MK2206
32 A Randomized Pilot Study to Evaluate the Effects of a Short Course of Metformin Versus No Therapy in the Period Prior to Hysterectomy for Grade 1-2 Adenocarcinoma of the Endometrium in Obese Non-Diabetic Women Completed NCT01877564 Phase 2 Metformin
33 A Phase II, Randomized Two-Arm Study of Everolimus and Letrozole, +/- Ribociclib (LEE011) in Patients With Advanced or Recurrent Endometrial Carcinoma Recruiting NCT03008408 Phase 2 Everolimus;Letrozole;Ribociclib
34 Phase II Study of the Levonorgestrel Intrauterine Device Alone or in Combination With the mTORC1 Inhibitor, Everolimus, for the Treatment of Complex Atypical Hyperplasia and Stage Ia Grade 1 Endometrial Cancer Recruiting NCT02397083 Phase 2 Everolimus
35 A Phase II Clinical Trial Evaluating the Combination of Onapristone With Anastrozole for Women With Refractory Hormone Receptor Positive Endometrial Cancer Recruiting NCT04719273 Phase 2 Extended-release Onapristone;Anastrozole
36 A Randomized Phase II Trial of Nivolumab and Ipilimumab Compared to Nivolumab Monotherapy in Patients With Deficient Mismatch Repair System Recurrent Endometrial Carcinoma Recruiting NCT05112601 Phase 2
37 A Phase 1b/2 Basket Study of ACR-368 as Monotherapy and in Combination With Gemcitabine in Adult Subjects With Platinum-Resistant Ovarian Carcinoma, Endometrial Adenocarcinoma, and Urothelial Carcinoma Based on Acrivon OncoSignature® Status Recruiting NCT05548296 Phase 1, Phase 2 ACR-368;Gemcitabine
38 A Phase 1/2a, Open-label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Anti-tumor Activity of PEN-866 in Patients With Advanced Solid Malignancies Recruiting NCT03221400 Phase 1, Phase 2 PEN-866 Sodium;fluorouracil;Folinic acid;Niraparib
39 Dose Escalation and Expansion Clinical Study to Evaluate the Safety and Efficacy of ELU001 in Subjects Who Have Advanced, Recurrent or Refractory FRα Overexpressing Tumors Recruiting NCT05001282 Phase 1, Phase 2 ELU001
40 Phase II Study of Fulvestrant in Combination With Abemaciclib in Hormone Receptor Positive Adenocarcinoma of Endometrium Recruiting NCT03643510 Phase 2 Fulvestrant;Abemaciclib
41 Pilot Study of Daily Exemestane in Women With Complex Atypical Hyperplasia of the Endometrium/Endometrial Intraepithelial Neoplasia or Low Grade Endometrial Cancer Active, not recruiting NCT03300557 Phase 2 Exemestane
42 A Randomized Trial of Pelvic Irradiation With or Without Concurrent Weekly Cisplatin in Patients With Pelvic-Only Recurrence of Carcinoma of the Uterine Corpus Active, not recruiting NCT00492778 Phase 2 Cisplatin
43 A Phase II Study of Tazemetostat (EPZ-6438) (IND # 138671) in Recurrent or Persistent Endometrioid or Clear Cell Carcinoma of the Ovary, and Recurrent or Persistent Endometrioid Endometrial Adenocarcinoma Active, not recruiting NCT03348631 Phase 2 Tazemetostat
44 A Phase II Study With a Limited Safety Lead-In of Enzalutamide in Combination With Carboplatin and Paclitaxel in Advanced Stage or Recurrent Endometrioid Endometrial Cancer Active, not recruiting NCT02684227 Phase 2 Carboplatin;Enzalutamide;Paclitaxel
45 A Multicentric, Randomized, Non Comparative, Open-label Phase I/II Evaluating AZD2014 (Dual Mammalian Target of Rapamycin Complex 1/2 (mTORC1/mTORC2) Inhibitor) in Combination With Anastrozole Versus Anastrozole Alone in the Treatment of Metastatic Hormone Receptor-positive Endometrial Adenocarcinoma Active, not recruiting NCT02730923 Phase 1, Phase 2 AZD2014;Anastrozole
46 A Phase II Trial of IDO-Inhibitor, BMS-986205, and PD-1 Inhibitor, Nivolumab, in Patients With Recurrent or Persistent Endometrial Cancer or Endometrial Carcinosarcomas (CA017-056) Active, not recruiting NCT04106414 Phase 2 Nivolumab;BMS- 986205
47 A Three Arm Randomized Phase II Study of Paclitaxel/Carboplatin/Bevacizumab (NSC #704865), Paclitaxel/Carboplatin/Temsirolimus (NSC #683864) and Ixabepilone (NSC #710428)/Carboplatin/Bevacizumab as Initial Therapy for Measurable Stage III or IVA, Stage IVB, or Recurrent Endometrial Cancer Active, not recruiting NCT00977574 Phase 2 Carboplatin;Ixabepilone;Paclitaxel;Temsirolimus
48 A Phase Ib Study of the Oral PARP Inhibitor Olaparib With the Oral mTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial, Triple Negative Breast, and Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Active, not recruiting NCT02208375 Phase 1, Phase 2 Capivasertib;Olaparib;Vistusertib
49 A Phase IB and Randomized Phase II Trial of Megestrol Acetate With or Without Ipatasertib in Recurrent or Metastatic Endometrioid Endometrial Cancer Not yet recruiting NCT05538897 Phase 1, Phase 2 Ipatasertib;Megestrol Acetate
50 A Phase II Trial of Trisenox in Women With Recurrent or Metastatic Endometrial Adenocarcinoma Terminated NCT01184053 Phase 2 Arsenic trioxide

Search NIH Clinical Center for Endometrial Adenocarcinoma

Genetic Tests for Endometrial Adenocarcinoma

Anatomical Context for Endometrial Adenocarcinoma

Organs/tissues related to Endometrial Adenocarcinoma:

MalaCards : Uterus, Lymph Node, Ovary, Breast, Endothelial, Cervix, Adipocyte

Publications for Endometrial Adenocarcinoma

Articles related to Endometrial Adenocarcinoma:

(show top 50) (show all 3766)
# Title Authors PMID Year
1
Prospective enterprise-level molecular genotyping of a cohort of cancer patients. 5
25157968 2014
2
The N550K/H mutations in FGFR2 confer differential resistance to PD173074, dovitinib, and ponatinib ATP-competitive inhibitors. 5
23908597 2013
3
FGFR genetic alterations predict for sensitivity to NVP-BGJ398, a selective pan-FGFR inhibitor. 5
23002168 2012
4
Lapatinib and potential prognostic value of EGFR mutations in a Gynecologic Oncology Group phase II trial of persistent or recurrent endometrial cancer. 5
22885469 2012
5
Ponatinib (AP24534), a multitargeted pan-FGFR inhibitor with activity in multiple FGFR-amplified or mutated cancer models. 5
22238366 2012
6
High frequency of PIK3R1 and PIK3R2 mutations in endometrial cancer elucidates a novel mechanism for regulation of PTEN protein stability. 5
21984976 2011
7
AKT1 pleckstrin homology domain E17K activating mutation in endometrial carcinoma. 5
19853286 2010
8
Drug-sensitive FGFR2 mutations in endometrial carcinoma. 5
18552176 2008
9
Expression profile of mammalian microRNAs in endometrioid adenocarcinoma. 46
19077565 2009
10
Iris metastasis from endometrial carcinoma: A challenging diagnosis and individualized eye-sparing treatment. 62
36388758 2022
11
A Constellation of Rare Gynecological Malignancies and Familial Adenomatous Polyposis Gastrointestinal Adenocarcinoma: A Case Report. 62
36302191 2022
12
Levonorgestrel-releasing intrauterine device plus metformin, or megestrol acetate plus metformin for fertility-sparing treatment of atypical endometrial hyperplasia and early endometrial carcinoma: a prospective, randomized, blind-endpoint design trial protocol. 62
36333773 2022
13
Metastatic Endometrioid Carcinoma Mimicking a Subungual Melanoma. 62
36361369 2022
14
VALIDATION OF A PANEL OF BIOMARKERS ASSOCIATED WITH AGGRESSIVE PHENOTYPE OF ENDOMETRIOID CARCINOMA OF ENDOMETRIUM. 62
36325701 2022
15
OPEC study: An international multicenter study of ovarian preservation in endometrial cancers. 62
35323994 2022
16
Significance of differential expression of OLFM4 in the development of endometrial adenocarcinoma. 62
36451436 2022
17
Platelet-derived exosomes induce cell proliferation and wound healing in human endometrial cells. 62
36193669 2022
18
Mesonephric-Like Adenocarcinomas a Rare Tumor: The Importance of Diagnosis. 62
36361332 2022
19
Adjuvant therapy in women with early stage uterine serous carcinoma: A multi-institutional study. 62
36243601 2022
20
[Aneurysm of the inferior vena cava : A case report]. 62
35718552 2022
21
Diagnostic utility of ThinPrep Imaging System® for detecting atypical glandular cells in cervical smear samples. 62
36308412 2022
22
Metastatic ovarian disease following surgical management of grade 1 endometrial endometrioid adenocarcinoma confined to the endometrium; a case report and review of the literature. 62
35967832 2022
23
Clinical and Biological Activity of Chemoimmunotherapy in Advanced Endometrial Adenocarcinoma: A Phase II Trial of the Big Ten Cancer Research Consortium. 62
36388466 2022
24
An MSH6 germline pathogenic variant p.Gly162Ter associated with Lynch syndrome. 62
36289196 2022
25
Loss of HOXA10 causes endometrial hyperplasia progressing to endometrial cancer. 62
35917434 2022
26
[Familial endometrial adenocarcinoma: MSH6 variant of unknown significance in the presence of phenocopy, what should be done?] 62
36075656 2022
27
Endometrial Cells Acutely Exposed to Phthalates In Vitro Do Not Phenocopy Endometriosis. 62
36232341 2022
28
[Retroperitoneal lymphadenopathy trans-vertebral image-guided biopsy: a case report] 62
36149066 2022
29
BAT26 Only Microsatellite Instability with High Tumor Mutation Burden-A Rare Entity Associated with PTEN Protein Loss and High PD-L1 Expression. 62
36142641 2022
30
12-O-Tetradecanoylphorbol 13-acetate promotes proliferation and epithelial-mesenchymal transition in HHUA cells cultured on collagen type I gel: A feasible model to find new therapies for endometrial diseases. 62
35973688 2022
31
The complex relationship between infertility and female genital tract cancer: A review. 62
34338095 2022
32
An unusual malignant main bile duct stricture: a biliary metastasis of endometrial adenocarcinoma. 62
35926532 2022
33
[Corrigendum] BMI‑1 promotes invasion and metastasis in endometrial adenocarcinoma and is a poor prognostic factor. 62
35730621 2022
34
The impact of uterine adenomyosis on the histopathological risk factors and survival in patients with endometrial adenocarcinoma. 62
35260040 2022
35
The role of potassium channels in the proliferation and migration of endometrial adenocarcinoma HEC1-A cells. 62
35553332 2022
36
Endometrial hyperplasia as a risk factor of endometrial cancer. 62
35001185 2022
37
Metastatic Cholangiocarcinoma to the Uterus Morphologically Imitating Primary Intestinal-type Endometrioid Adenocarcinoma. 62
36044318 2022
38
Intestinal type adenocarcinoma of the endometrium with signet ring cells, a rare aggressive variant. 62
35898198 2022
39
Indications for Adjuvant Radiation Therapy in Patients With pN0(i +) Adenocarcinoma of the Endometrium. 62
35248784 2022
40
DSCAM-AS1 Long Non-Coding RNA Exerts Oncogenic Functions in Endometrial Adenocarcinoma via Activation of a Tumor-Promoting Transcriptome Profile. 62
35885035 2022
41
Ichthyosis uteri associated with squamous cell carcinoma of the endometrium - a case report. 62
35848086 2022
42
Safety of ovarian preservation for premenopausal patients with FIGO stage I grade 2 and 3 endometrioid endometrial adenocarcinoma. 62
35882426 2022
43
An Evaluation of the Immunohistochemical Expression of Mismatch Repair Proteins (MSH2, MSH6, MLH1, and PMS2) in Prostate Adenocarcinoma. 62
36051725 2022
44
Synchronous benign Brenner's tumor of the ovary with leiomyoma and endometrial adenocarcinoma in a postmenopausal female. 62
36149192 2022
45
First pointwise encoding time reduction with radial acquisition (PETRA) implementation for catheter detection in interstitial high-dose-rate (HDR) brachytherapy. 62
35337748 2022
46
Ruptured granulosa cell tumor of the ovary presenting with catastrophic intra-abdominal hemorrhage: A case report. 62
35724501 2022
47
The impact of tumor size and histology on local control when utilizing high-dose-rate interstitial brachytherapy for gynecologic malignancies. 62
35370010 2022
48
Development and Validation of an MRI-based Radiomics Nomogram for Assessing Deep Myometrial Invasion in Early Stage Endometrial Adenocarcinoma. 62
35778306 2022
49
YTHDF2 is a novel diagnostic marker of endometrial adenocarcinoma and endometrial atypical hyperplasia/ intraepithelial neoplasia. 62
35512522 2022
50
Histopathological and genetic features of mismatch repair-deficient high-grade prostate cancer. 62
35395112 2022

Variations for Endometrial Adenocarcinoma

ClinVar genetic disease variations for Endometrial Adenocarcinoma:

5 (show all 18)
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 EGFR NM_005228.5(EGFR):c.2068G>A (p.Glu690Lys) SNV Likely Pathogenic
376152 rs1057519794 GRCh37: 7:55241620-55241620
GRCh38: 7:55173927-55173927
2 PIK3R2 NM_005027.4(PIK3R2):c.1681A>G (p.Asn561Asp) SNV Likely Pathogenic
376165 rs1057519801 GRCh37: 19:18278061-18278061
GRCh38: 19:18167251-18167251
3 AKT1 NM_001382430.1(AKT1):c.49G>A (p.Glu17Lys) SNV Likely Pathogenic
13983 rs121434592 GRCh37: 14:105246551-105246551
GRCh38: 14:104780214-104780214
4 FGFR2 NM_000141.5(FGFR2):c.1975A>G (p.Lys659Glu) SNV Likely Pathogenic
376153 rs1057519795 GRCh37: 10:123247516-123247516
GRCh38: 10:121488002-121488002
5 FGFR2 NM_000141.5(FGFR2):c.1605G>A (p.Met535Ile) SNV Likely Pathogenic
376164 rs1057519800 GRCh37: 10:123258076-123258076
GRCh38: 10:121498562-121498562
6 FGFR2 NM_000141.5(FGFR2):c.1690G>A (p.Val564Ile) SNV Likely Pathogenic
376155 rs1057519797 GRCh37: 10:123256219-123256219
GRCh38: 10:121496705-121496705
7 FGFR2 NM_000141.5(FGFR2):c.1605G>T (p.Met535Ile) SNV Likely Pathogenic
376162 rs1057519800 GRCh37: 10:123258076-123258076
GRCh38: 10:121498562-121498562
8 FGFR2 NM_000141.5(FGFR2):c.1611G>T (p.Met537Ile) SNV Likely Pathogenic
376159 rs1057519799 GRCh37: 10:123258070-123258070
GRCh38: 10:121498556-121498556
9 FGFR2 NM_000141.5(FGFR2):c.1849T>A (p.Leu617Met) SNV Likely Pathogenic
376154 rs1057519796 GRCh37: 10:123256060-123256060
GRCh38: 10:121496546-121496546
10 FGFR2 NM_000141.5(FGFR2):c.755C>G (p.Ser252Trp) SNV Likely Pathogenic
13272 rs79184941 GRCh37: 10:123279677-123279677
GRCh38: 10:121520163-121520163
11 FGFR2 NM_000141.5(FGFR2):c.1645A>C (p.Asn549His) SNV Likely Pathogenic
374821 rs1057519045 GRCh37: 10:123258036-123258036
GRCh38: 10:121498522-121498522
12 FGFR2 NM_000141.5(FGFR2):c.1647T>A (p.Asn549Lys) SNV Likely Pathogenic
376157 rs121913476 GRCh37: 10:123258034-123258034
GRCh38: 10:121498520-121498520
13 FGFR2 NM_000141.5(FGFR2):c.1647T>G (p.Asn549Lys) SNV Likely Pathogenic
376156 rs121913476 GRCh37: 10:123258034-123258034
GRCh38: 10:121498520-121498520
14 FGFR2 NM_000141.5(FGFR2):c.1605G>C (p.Met535Ile) SNV Likely Pathogenic
376163 rs1057519800 GRCh37: 10:123258076-123258076
GRCh38: 10:121498562-121498562
15 FGFR2 NM_000141.5(FGFR2):c.1611G>C (p.Met537Ile) SNV Likely Pathogenic
376160 rs1057519799 GRCh37: 10:123258070-123258070
GRCh38: 10:121498556-121498556
16 FGFR2 NM_000141.5(FGFR2):c.1694A>G (p.Glu565Gly) SNV Likely Pathogenic
374823 rs121918506 GRCh37: 10:123256215-123256215
GRCh38: 10:121496701-121496701
17 FGFR2 NM_000141.5(FGFR2):c.1611G>A (p.Met537Ile) SNV Likely Pathogenic
376161 rs1057519799 GRCh37: 10:123258070-123258070
GRCh38: 10:121498556-121498556
18 FGFR2 NM_000141.5(FGFR2):c.1639A>G (p.Ile547Val) SNV Likely Pathogenic
376158 rs1057519798 GRCh37: 10:123258042-123258042
GRCh38: 10:121498528-121498528

Cosmic variations for Endometrial Adenocarcinoma:

8 (show top 50) (show all 13016)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM147988734 TSC1 endometrium,NS,carcinoma,adenocarcinoma c.2695C>G p.Q899E 9:132897538-132897538 15
2 COSM151335840 TSC1 endometrium,NS,carcinoma,adenocarcinoma c.2698C>G p.Q900E 9:132897538-132897538 15
3 COSM111045067 TSC1 endometrium,NS,carcinoma,adenocarcinoma c.2698C>G p.Q900E 9:132897538-132897538 15
4 COSM148040940 TSC1 endometrium,NS,carcinoma,adenocarcinoma c.2680C>G p.Q894E 9:132897538-132897538 15
5 COSM151876398 TSC1 endometrium,NS,carcinoma,adenocarcinoma c.2698C>G p.Q900E 9:132897538-132897538 15
6 COSM150680210 TSC1 endometrium,NS,carcinoma,adenocarcinoma c.2683C>G p.Q895E 9:132897538-132897538 15
7 COSM150540031 TSC1 endometrium,NS,carcinoma,adenocarcinoma c.2545C>G p.Q849E 9:132897538-132897538 15
8 COSM149044571 TSC1 endometrium,NS,carcinoma,adenocarcinoma c.2695C>G p.Q899E 9:132897538-132897538 15
9 COSM85725394 TSC1 endometrium,NS,carcinoma,adenocarcinoma c.2698C>G p.Q900E 9:132897538-132897538 15
10 COSM133092250 TSC1 endometrium,NS,carcinoma,adenocarcinoma c.2545C>G p.Q849E 9:132897538-132897538 15
11 COSM93207461 TP53 endometrium,NS,carcinoma,adenocarcinoma c.761T>G p.I254S 17:7674202-7674202 15
12 COSM144099306 TP53 endometrium,NS,carcinoma,adenocarcinoma c.-89T>G p.? 17:7675223-7675223 15
13 COSM112253807 TP53 endometrium,NS,carcinoma,adenocarcinoma c.733G>A p.G245S 17:7674230-7674230 15
14 COSM87925973 TP53 endometrium,NS,carcinoma,adenocarcinoma c.761T>G p.I254S 17:7674202-7674202 15
15 COSM143157028 TP53 endometrium,NS,carcinoma,adenocarcinoma c.340C>T p.R114C 17:7673803-7673803 15
16 COSM143162603 TP53 endometrium,NS,carcinoma,adenocarcinoma c.217A>G p.I73V 17:7674269-7674269 15
17 COSM142560558 TP53 endometrium,NS,carcinoma,adenocarcinoma c.727C>T p.R243W 17:7673776-7673776 15
18 COSM121901025 TP53 endometrium,NS,carcinoma,adenocarcinoma c.365T>G p.I122S 17:7674202-7674202 15
19 COSM111759017 TP53 endometrium,NS,carcinoma,adenocarcinoma c.722C>G p.S241C 17:7674241-7674241 15
20 COSM122734486 TP53 endometrium,NS,carcinoma,adenocarcinoma c.520C>T p.R174* 17:7673704-7673704 15
21 COSM144100203 TP53 endometrium,NS,carcinoma,adenocarcinoma c.26A>G p.H9R 17:7675109-7675109 15
22 COSM121876472 TP53 endometrium,NS,carcinoma,adenocarcinoma c.448C>T p.R150W 17:7673776-7673776 15
23 COSM121881481 TP53 endometrium,NS,carcinoma,adenocarcinoma c.445G>A p.D149N 17:7673779-7673779 15
24 COSM144651436 TP53 endometrium,NS,carcinoma,adenocarcinoma c.625C>T p.R209W 17:7674221-7674221 15
25 COSM143946029 TP53 endometrium,NS,carcinoma,adenocarcinoma c.*43C>T p.? 17:7670685-7670685 15
26 COSM87917930 TP53 endometrium,NS,carcinoma,adenocarcinoma c.503A>G p.H168R 17:7675109-7675109 15
27 COSM144087273 TP53 endometrium,NS,carcinoma,adenocarcinoma c.265C>T p.R89W 17:7674221-7674221 15
28 COSM144653327 TP53 endometrium,NS,carcinoma,adenocarcinoma c.*131C>T p.? 17:7670685-7670685 15
29 COSM144675014 TP53 endometrium,NS,carcinoma,adenocarcinoma c.644T>G p.I215S 17:7674202-7674202 15
30 COSM142566974 TP53 endometrium,NS,carcinoma,adenocarcinoma c.577A>G p.I193V 17:7674269-7674269 15
31 COSM93185597 TP53 endometrium,NS,carcinoma,adenocarcinoma c.637C>T p.R213* 17:7674894-7674894 15
32 COSM145018055 TP53 endometrium,NS,carcinoma,adenocarcinoma c.799C>T p.R267* 17:7673704-7673704 15
33 COSM112253979 TP53 endometrium,NS,carcinoma,adenocarcinoma c.916C>T p.R306* 17:7673704-7673704 15
34 COSM122275678 TP53 endometrium,NS,carcinoma,adenocarcinoma c.445G>A p.D149N 17:7673779-7673779 15
35 COSM143157019 TP53 endometrium,NS,carcinoma,adenocarcinoma c.265C>T p.R89W 17:7674221-7674221 15
36 COSM144659060 TP53 endometrium,NS,carcinoma,adenocarcinoma c.577A>G p.I193V 17:7674269-7674269 15
37 COSM142562047 TP53 endometrium,NS,carcinoma,adenocarcinoma c.520C>T p.R174* 17:7674894-7674894 15
38 COSM143158609 TP53 endometrium,NS,carcinoma,adenocarcinoma c.*131C>T p.? 17:7670685-7670685 15
39 COSM122750344 TP53 endometrium,NS,carcinoma,adenocarcinoma c.107A>G p.H36R 17:7675109-7675109 15
40 COSM144088597 TP53 endometrium,NS,carcinoma,adenocarcinoma c.547C>T p.R183* 17:7670685-7670685 15
41 COSM142837646 TP53 endometrium,NS,carcinoma,adenocarcinoma c.916C>T p.R306* 17:7673704-7673704 15
42 COSM143958875 TP53 endometrium,NS,carcinoma,adenocarcinoma c.26A>G p.H9R 17:7675109-7675109 15
43 COSM144090100 TP53 endometrium,NS,carcinoma,adenocarcinoma c.364G>A p.D122N 17:7673779-7673779 15
44 COSM143949774 TP53 endometrium,NS,carcinoma,adenocarcinoma c.217A>G p.I73V 17:7674269-7674269 15
45 COSM93184097 TP53 endometrium,NS,carcinoma,adenocarcinoma c.916C>T p.R306* 17:7673704-7673704 15
46 COSM111763404 TP53 endometrium,NS,carcinoma,adenocarcinoma c.841G>A p.D281N 17:7673779-7673779 15
47 COSM111765865 TP53 endometrium,NS,carcinoma,adenocarcinoma c.694A>G p.I232V 17:7674269-7674269 15
48 COSM105620760 TP53 endometrium,NS,carcinoma,adenocarcinoma c.782+477C>T p.? 17:7673704-7673704 15
49 COSM121893481 TP53 endometrium,NS,carcinoma,adenocarcinoma c.-8T>G p.? 17:7675223-7675223 15
50 COSM143156960 TP53 endometrium,NS,carcinoma,adenocarcinoma c.256G>A p.G86S 17:7674230-7674230 15

Expression for Endometrial Adenocarcinoma

Search GEO for disease gene expression data for Endometrial Adenocarcinoma.

Pathways for Endometrial Adenocarcinoma

Pathways related to Endometrial Adenocarcinoma according to GeneCards Suite gene sharing:

(show top 50) (show all 51)
# Super pathways Score Top Affiliating Genes
1 13.75 TP53 PTEN PIK3R2 PGR NDC80 FGFR2
2
Show member pathways
13.02 TP53 PTEN PIK3R2 FGFR2 EGFR AKT1
3
Show member pathways
12.92 AKT1 EGFR ESR1 FGFR2 PIK3R2 PTEN
4
Show member pathways
12.89 TP53 PTEN PIK3R2 FGFR2 EGFR AKT1
5
Show member pathways
12.83 PTEN PIK3R2 FGFR2 EGFR AKT1
6 12.73 PIK3R2 PGR FGFR2 ESR1 EGFR AKT1
7 12.64 TP53 PTEN FGFR2 EGFR AKT1
8
Show member pathways
12.61 TP53 PIK3R2 FGFR2 EGFR AKT1
9
Show member pathways
12.53 TP53 PTEN PIK3R2 FGFR2 EGFR AKT1
10
Show member pathways
12.46 AKT1 EGFR PIK3R2 TP53
11
Show member pathways
12.45 PTEN PIK3R2 FGFR2 ESR1 EGFR AKT1
12
Show member pathways
12.38 PIK3R2 ESR1 EGFR AKT1
13 12.37 TP53 FGFR2 EGFR AKT1
14
Show member pathways
12.34 TP53 PTEN PIK3R2 ESR1 AKT1
15
Show member pathways
12.31 TP53 PIK3R2 FGFR2 EGFR AKT1
16
Show member pathways
12.28 PIK3R2 ESR1 EGFR AKT1
17 12.24 AKT1 EGFR PIK3R2 PTEN
18
Show member pathways
12.21 TP53 PTEN PIK3R2 AKT1
19 12.19 PIK3R2 FGFR2 EGFR AKT1
20
Show member pathways
12.15 PTEN FGFR2 EGFR AKT1
21 12.13 AKT1 EGFR PIK3R2 TP53
22
Show member pathways
11.98 AKT1 EGFR FGFR2 PIK3R2 PTEN TP53
23
Show member pathways
11.94 AKT1 EGFR PIK3R2 TP53
24 11.91 TP53 PTEN PIK3R2 ESR1 EGFR AKT1
25 11.89 TP53 PTEN PIK3R2
26
Show member pathways
11.87 PTEN PIK3R2 EGFR AKT1
27 11.86 PIK3R2 ESR1 AKT1
28 11.84 PTEN PIK3R2 AKT1
29 11.81 TP53 PTEN AKT1
30 11.8 AKT1 EGFR PTEN
31 11.78 TP53 PTEN PIK3R2 FGFR2 EGFR AKT1
32
Show member pathways
11.76 TP53 PIK3R2 AKT1
33 11.74 TP53 PTEN PIK3R2 AKT1
34 11.73 TP53 FGFR2 AKT1
35 11.71 TP53 PTEN ESR1
36 11.68 TP53 PTEN ESR1
37 11.67 ESR1 EGFR AKT1
38
Show member pathways
11.66 TP53 PTEN PIK3R2 PGR FGFR2 ESR1
39 11.62 TP53 PTEN AKT1
40
Show member pathways
11.58 TP53 PTEN AKT1
41 11.38 TP53 PIK3R2 EGFR
42 11.36 TP53 PTEN ESR1
43 11.34 MIR200B MIR200A MIR148B
44 11.33 TP53 PTEN AKT1
45 11.3 TP53 PIK3R2 EGFR
46 11.3 TP53 PTEN PIK3R2 FGFR2 EGFR AKT1
47 11.25 PGR ESR1 EGFR
48 11.2 PTEN PIK3R2 AKT1
49 10.84 MIR200B MIR200A AKT1
50 10.81 PGR ESR1

GO Terms for Endometrial Adenocarcinoma

Cellular components related to Endometrial Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 RISC complex GO:0016442 9.4 MIR204 MIR202 MIR200B MIR200A MIR152 MIR148B

Biological processes related to Endometrial Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 negative regulation of gene expression GO:0010629 10.03 TP53 PGR MIR200B ESR1 AKT1
2 phosphatidylinositol 3-kinase signaling GO:0014065 9.85 AKT1 PIK3R2 PTEN
3 prostate epithelial cord arborization involved in prostate glandular acinus morphogenesis GO:0060527 9.71 FGFR2 ESR1
4 negative regulation of miRNA maturation GO:1903799 9.65 TP53 ESR1
5 positive regulation of RNA polymerase II transcription preinitiation complex assembly GO:0045899 9.62 TP53 ESR1
6 positive regulation of miRNA maturation GO:1903800 9.46 TP53 EGFR
7 response to UV-A GO:0070141 9.46 EGFR AKT1
8 cellular response to decreased oxygen levels GO:0036294 9.43 PTEN AKT1
9 prostate epithelial cord elongation GO:0060523 9.26 FGFR2 ESR1
10 negative regulation of blood vessel endothelial cell migration GO:0043537 8.92 MIR204 MIR200B MIR193A MIR152

Molecular functions related to Endometrial Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 enzyme binding GO:0019899 10.03 TP53 PTEN PGR ESR1 EGFR AKT1
2 nitric-oxide synthase regulator activity GO:0030235 9.63 ESR1 EGFR AKT1
3 mRNA 3'-UTR binding GO:0003730 9.5 TP53 MIR204 MIR200B MIR193A MIR152 MIR148B
4 mRNA base-pairing translational repressor activity GO:1903231 9.1 MIR204 MIR200B MIR200A MIR193A MIR152 MIR148B

Sources for Endometrial Adenocarcinoma

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....